Table 4 Univariate and multivariate analyses of adverse factors associated with II–IV aGVHD and CMV viremia.
Outcome | No. of events/evaluable (100-day cumulative incidence %) | Univariate | Multivariate | |
|---|---|---|---|---|
P value (fine gray) | P value (fine gray) | Hazard ratio (95% confidence interval) | ||
Liver events after HSCT | ||||
Interval from diagnosis to HSCT, days | 0.004*# | 0.005* | 6.9 (1.8–27.0) | |
< = 75 | 3/18 (17.0%) | |||
> 75 | 11/17 (64.7%) | |||
HID group | 0.363# | 0.150 | ||
HID | 6/18 (33.3%) | |||
MSD | 8/17 (47.7%) | |||
IST before HSCT | 0.034*# | 0.240 | ||
ATG-based | 2/2 (100.0%) | |||
CsA-based | 5/22 (22.7%) | |||
No | 7/11 (63.6%) | |||
II–IV aGVHD | ||||
PLT at diagnosis, 1012/L | 0.017*# | 0.215 | ||
< 10 | 9/15 (60.0%) | |||
> = 10 | 4/20 (20.0%) | |||
Donor age, years | 0.054# | 0.017* | 6.8 (1.6–21.3) | |
< 20 | 1/9 (11.1%) | |||
> = 20 | 12/25 (48.0%) | |||
Donor sex | 0.024*# | 0.005* | 5.6 (1.7–18.7) | |
Female donor | 8/13 (61.5%) | |||
Male donor | 5/22 (22.7%) | |||
CMV viremia | ||||
Patient age at transplantation, years | 0.067# | 0.870 | ||
9–19 | 7/15 (49.7%) | |||
20–29 | 1/10 (11.1%) | |||
30–39 | 6/9 (66.7%) | |||
40– | 0/1 (0.0%) | |||
Donor type | 0.010*# | 0.002* | 6.6 (2.0–21.2) | |
HID | 11/18 (64.1%) | |||
MSD | 3/17 (17.6%) | |||
Conditioning regimen | 0.149# | 0.333 | ||
Bu + Cy + Flu + ATG | 4/6 (66.7%) | |||
Cy + Flu + ATG | 10/29 (35.5%) | |||
